Sandoz unveils Bio 100 strategy to launch 100+ biosimilars by 2040
Company says Bio 100 strategy targets launching over 100 biosimilars by 2040. It aims to double net sales by 2035 and reach a core EBITDA margin above 30%, backed by vertical integration and regulatory streamlining.
The company unveiled its Bio 100 strategy to launch over 100 biosimilars by 2040, with a target to double net sales by 2035 and lift its core EBITDA margin above 30%. The plan is supported by investments in vertical integration, regulatory streamlining and global commercial execution.